4D Molecular Therapeutics Inc (FDMT) Actualités

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70...

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be...

Form 8-K - Current report

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest...

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic...

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase...